PTC THERAPEUTICS, INC. — Director's Dealing 2021

Jan 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2021-01-08

Reporting Person: Hill Emily Luisa (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-08	Common Stock	M	2430	$30.86	Acquired	26552	Direct
2021-01-08	Common Stock	S	2430	$69.75	Disposed	24122	Direct
2021-01-08	Common Stock	M	3825	$11.23	Acquired	27947	Direct
2021-01-08	Common Stock	S	3825	$69.75	Disposed	24122	Direct
2021-01-08	Common Stock	M	10500	$18.01	Acquired	34622	Direct
2021-01-08	Common Stock	S	10500	$69.75	Disposed	24122	Direct
2021-01-08	Common Stock	M	9278	$33.02	Acquired	33400	Direct
2021-01-08	Common Stock	S	9278	$69.75	Disposed	24122	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-08	Stock Option (Right To Buy)	$30.86	M	2430	Disposed	2026-01-03	Common Stock (2430.0)	Direct
2021-01-08	Stock Option (Right To Buy)	$11.23	M	3825	Disposed	2027-01-02	Common Stock (3825.0)	Direct
2021-01-08	Stock Option (Right To Buy)	$18.01	M	10500	Disposed	2028-01-03	Common Stock (10500)	Direct
2021-01-08	Stock Option (Right To Buy)	$33.02	M	9278	Disposed	2029-01-21	Common Stock (9278)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right To Buy)	$43.69	2024-09-24	Common Stock (7000.0)	7000	Direct
Stock Option (Right To Buy)	$51.0	2025-01-02	Common Stock (1620.0)	1620	Direct
Stock Option (Right To Buy)	$40.1	2029-05-30	Common Stock (50000.0)	50000	Direct
Stock Option (Right to Buy)	$51.16	2030-01-28	Common Stock (64250)	64250	Direct
Stock Option (Right to Buy)	$66.49	2031-01-05	Common Stock (63000)	63000	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020.

F2: Currently exercisable.

F3: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

F4: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.

F5: This option was granted on May 31, 2019 and vests over four years, with 25% of the shares underlying the option vesting on May 31, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning August 31, 2020.

F6: This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.

F7: This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.